Skip to main content
Smart Investors Daily
AN

NASDAQ · ANL

Adlai Nortye Ltd.

Healthcare · Biotechnology

$10.03

Down-$0.58 (-5.47%)

Updated Nov 17, 2026, 2:38 AM

SID Score

4.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
245.52M
P/E ratio
-1.61
Dividend yield
0.00%
52-week range
$0.88 – $17.25
Volume
172.08K
Avg. volume
920.81K

Price performance · ANL

ANL price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 16, 2026

ANL closed at $10.03 after 21 trading sessions, down 3.37% for the selected period.

Last close
$10.03
Period change
-3.37%
Period low
$9.37
Period high
$11.26
Daily close
View OHLC price history
ANL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 16, 2026$10.60$11.00$9.79$10.03172.08K
Nov 13, 2026$10.52$10.91$9.91$10.61152.06K
Nov 12, 2026$10.62$10.79$10.22$10.52130.65K
Nov 11, 2026$10.03$11.22$9.76$10.85195.93K
Nov 10, 2026$10.98$11.15$9.46$9.96377.01K
Nov 9, 2026$9.85$11.45$9.85$11.15263.35K
Nov 6, 2026$9.77$10.70$9.43$10.28531.01K
Nov 5, 2026$9.61$9.85$8.90$9.68450.32K
Nov 4, 2026$9.70$10.06$9.02$9.61238.62K
Nov 3, 2026$9.39$9.925$9.35$9.58236.14K
Nov 2, 2026$9.75$9.95$9.21$9.37272.63K
Oct 30, 2026$10.11$10.13$9.36$9.55262.1K
Oct 29, 2026$10.20$10.68$10.20$10.2844.56K
Oct 28, 2026$10.72$11.15$10.04$10.20125.34K
Oct 27, 2026$10.63$11.095$10.54$10.7171.16K
Oct 26, 2026$10.71$10.88$10.40$10.58132.94K
Oct 23, 2026$10.55$10.65$10.30$10.5879.54K
Oct 22, 2026$11.01$11.22$10.58$10.58169.97K
Oct 21, 2026$10.80$11.68$10.80$11.26532.6K
Oct 20, 2026$10.37$11.32$10.37$10.64242.56K
Oct 19, 2026$10.97$11.38$10.34$10.38356.48K

Latest ANL news

The latest Smart Investors Daily articles mentioning ANL.

ANL research

Overview

Company profile and research snapshot.

Company profile

Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$9.00
Implied upside
—
Analysts
—
ANL recent ratings
DateFirmRatingTarget
Sep 10, 2026JefferiesBuy—
Sep 8, 2026HC Wainwright & Co.Buy—
Jun 22, 2026Cantor FitzgeraldOverweight—
May 28, 2026OppenheimerOutperform—
May 14, 2026Jones TradingBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 27, 2026

Adlai Nortye Announces Oral Presentation for AN4035 Program Update at the Upcoming 38th EORTC-NCI-AACR Symposium

AN4035 late-breaking abstract selected for an oral presentation at the upcoming ENA Symposium in Barcelona Oral presentation will include translational and EGFR combination data for first-in-class AN4035 AN4035 is a novel CEACAM5-targeting ADC armed with a proprietary pan-RAS(ON) inhibitor payload, designed to broaden the therapeutic window SINGAPORE and NORTH BRUNSWICK, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-st

Yahoo · Oct 15, 2026

Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab

AN4035, a first-in-class investigational pan-RAS(ON) inhibitor-based ADC, will be evaluated as monotherapy and in combination with cetuximab in the ongoing global Phase I trial Cetuximab will be supplied by Lilly for the U.S. trial sites Cetuximab will be supplied by Merck KGaA, Darmstadt, Germany for the Australia and China trial sites SINGAPORE and NORTH BRUNSWICK, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.